OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Azad on Treatment Considerations in Right- Versus Left-Sided CRC

October 16th 2020

Nilofer Saba Azad, MD, discusses treatment considerations in right- versus left-sided colorectal cancer.

Dr. Marshall on Challenges With Sequencing in CRC

October 15th 2020

John L. Marshall, MD, discusses sequencing challenges in colorectal cancer.

Dr. Siena on the Rationale for the DESTINY-CRC01 in Metastatic CRC

October 15th 2020

Salvatore Siena, MD, discusses the rationale for the phase 2 DESTINY-CRC01 trial in metastatic colorectal cancer.

Dr. Azad on Remaining Challenges in CRC

October 15th 2020

Nilofer Saba Azad, MD, discusses remaining challenges in colorectal cancer.

Dr. Schwartz on Future Research Efforts in Sarcoma

October 15th 2020

Gary K. Schwartz, MD, discusses future research efforts in the field of sarcoma.

Dr. Bose on Current Treatment Options for Essential Thrombocythemia

October 15th 2020

Prithviraj Bose, MD, discusses current treatment options for essential thrombocythemia.

Dr. Mesa on Remaining Challenges Faced in MPN Treatment

October 15th 2020

Ruben A. Mesa, MD, discusses remaining challenges faced in the treatment of patients with myeloproliferative neoplasms.

Dr. Bhat on the Potential for Time-Limited Combinations in CLL

October 15th 2020

Seema A. Bhat, MD, discusses the potential for time-limited combination regimens in chronic lymphocytic leukemia.

Dr. Ma on Developing Novel Agents in BTK Inhibitor–Resistant CLL

October 15th 2020

Shuo Ma, MD, PhD, discusses the need to develop novel agents to treat patients with chronic lymphocytic leukemia who develop resistance to BTK inhibitors.

Dr. Davids on Investigational Doublets and Triplets in CLL

October 15th 2020

Matthew S. Davids, MD, MMSc, discusses investigational doublets and triplets in chronic lymphocytic leukemia.

Dr. Visco on Results from the MANTLE-FIRST Study in Relapsed/Refractory MCL

October 15th 2020

Carlo Visco, MD, discusses the results of early relapse versus late relapse in the MANTLE-FIRST study with ibrutinib versus chemoimmunotherapy in mantle cell lymphoma.

Dr. Shore on the HERO Trial With Relugolix in Advanced Prostate Cancer

October 15th 2020

Neal D. Shore, MD, FACS, discusses the results from the phase 3 HERO trial with relugolix in men with advanced prostate cancer.

Dr. Kopetz on the Design of the BEACON CRC Trial in BRAF V600E-Mutant mCRC

October 15th 2020

Scott Kopetz, MD, PhD, FACP, discusses the design of the phase 3 BEACON CRC trial in metastatic colorectal cancer.

Dr. Bekaii-Saab on the Emergence of Targeted Therapy in CRC

October 14th 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses the emergence of targeted therapy in colorectal cancer.

Dr. Chu on the Importance of Identifying MSI Status in mCRC

October 14th 2020

Edward Chu, MD, MMS, discusses the importance of identifying patients with microsatellite instability–high metastatic colorectal cancer.

Dr. Nazha on the Potential Role of Ropeginterferon Alfa-2b in Polycythemia Vera

October 14th 2020

Aziz Nazha, MD, discusses the potential role of ropeginterferon alfa-2b in polycythemia vera.

Dr. Maki on the Potential Utility of Immunotherapy in Sarcoma

October 14th 2020

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the potential utility of immunotherapy in sarcoma.

Dr. Bhat on Emerging Targeted Therapies in CLL

October 14th 2020

Seema A. Bhat, MD, emerging targeted therapies in chronic lymphocytic leukemia.

Dr. Hussain on Rationale to Explore Relationship Between PSA and Outcomes in Nonmetastatic CRPC

October 13th 2020

Maha Hussain, MD, FACP, FASCO, discusses the design of the phase 3 PROSPER trial in patients with nonmetastatic castration-resistant prostate cancer.

Dr. Galligan the Utility of Up-front High-Intensity Therapy in Multiple Myeloma

October 13th 2020

Derek C. Galligan, MD, discusses the utility of up-front high-intensity therapy for patients with multiple myeloma.